Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for the clinical trial of Ruvelimab tablets, which will commence shortly [1] Group 1: Company Developments - The company has been granted a "Drug Clinical Trial Approval Notice" for Ruvelimab tablets [1] - Ruvelimab tablets are classified as a second-generation AR inhibitor, offering stronger AR inhibition compared to first-generation AR inhibitors [1] - The new drug is noted for having no agonistic effects, distinguishing it from earlier treatments [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的全部內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 ASCENTAGE PHARMA GROUP INTERNATIONAL 亞盛醫藥集團 （於開曼群島註冊成立的有限公司） （股份代號：6855） 自願公告 亞盛醫藥耐立克®、利生妥®、APG-5918的多項臨床進展將 在2025年美國血液學會年會(ASH)展示，其中一項獲口頭報告 亞盛醫藥集團（「本公司」或「亞盛醫藥」）欣然宣佈，本公司3個品種（耐立克®、利 生妥®、APG-5918）有多項臨床和臨床前進展入選第67屆美國血液學會(American Society of Hematology, ASH)年會展示及報告，其中一項獲口頭報告。其中，本 公司原創1類新藥奧雷巴替尼（商品名：耐立克®）有多項臨床進展獲選第67屆ASH 年會，這是該品種的臨床進展連續第8年入選ASH年會。此外，本公司原創1類新 藥利沙托克拉（商品名：利生妥®；研發代碼：APG-2575）共有2項臨床進展獲選 第67屆ASH年會， ...

Core Viewpoint - The announcement highlights that Yichang Renfu Pharmaceutical, a subsidiary of Renfu Pharmaceutical, has received approval from the National Medical Products Administration for the clinical trial of Pregabalin sustained-release tablets, indicating a significant step in expanding its treatment applications [1] Company Summary - Renfu Pharmaceutical holds an 80% stake in Yichang Renfu Pharmaceutical, which has recently been granted a clinical trial approval for Pregabalin sustained-release tablets [1] - The initial approval in 2023 was for the treatment of diabetic peripheral neuropathy (DPN) related neuropathic pain, and the new application aims to include postherpetic neuralgia (PHN) as an additional indication [1] Industry Summary - Pregabalin is identified as a novel calcium channel modulator that effectively blocks voltage-dependent calcium channels, thereby reducing the release of neurotransmitters [1] - The clinical applications of Pregabalin primarily target neuropathic pain associated with DPN and PHN, which are significant areas in pain management within the pharmaceutical industry [1]

Core Insights - The webinar discusses a recently published paper in eBioMedicine, part of the Lancet Discovery Group Journals, highlighting the results of a study conducted by Intensity Therapeutics [2] Group 1: Company Overview - Intensity Therapeutics is led by Lewis H. Bender, who serves as the Founder, President, CEO, and Chairman of the Board [2] - The company is focused on clinical trials for its drug INT230-6, with expectations for future performance being a key topic of discussion [3] Group 2: Study Results - The company expressed excitement about the results of the study, indicating a positive outlook for the findings presented in the paper [2]

Core Insights - The conference call focuses on the top line results from Part B of the Phase Ib clinical trial evaluating TX45 for patients with pulmonary hypertension associated with reduced ejection fraction heart failure (PH-HFrEF) [2][3] Group 1: Clinical Trial Overview - The clinical trial involved 14 patients and aimed to assess the safety and tolerability of TX45 in the PH-HFrEF patient population [3] - The trial also sought to explore the hemodynamic effects of TX45, with expectations of observing effects similar to previous studies [3]

Core Viewpoint - Inhibrx Biosciences, Inc. announced positive primary results from the ChonDRAgon clinical study, evaluating the efficacy of ozekibart (INBRX-109) in patients with advanced or metastatic, unresectable chondrosarcoma compared to placebo [1] Group 1: Clinical Study Results - The ChonDRAgon study involved 206 participants and demonstrated significant improvement in progression-free survival (PFS) for chondrosarcoma patients treated with ozekibart [1] - Ozekibart is the first investigational drug to show a significant improvement in PFS in a randomized controlled trial for this patient population [1] Group 2: Regulatory and Market Implications - Inhibrx plans to submit a New Drug Application (NDA) to the U.S. regulatory authorities for ozekibart's chondrosarcoma indication by the end of June 2026 [1] - The company holds exclusive development and commercialization rights for ozekibart in mainland China, Hong Kong, Macau, and Taiwan through its wholly-owned subsidiary, HJB [1] Group 3: Market Context - Currently, there are no approved systemic treatment options for chondrosarcoma, highlighting the potential market value of ozekibart for global patients and in the regions where the company has exclusive rights [1]

本公告由創勝集團醫藥有限公司（「本公司」）自願作出，旨在告知本公司股東及潛 在投資者有關最新業務進展。本公告所用但並無另行界定的詞彙應與本公司日期 為2021年9月14日的招股章程中所賦予該等詞彙的涵義相同。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Transcenta Holding Limited 創勝集團醫藥有限公司 （以存續方式於開曼群島註冊的有限公司） （股份代號：6628） 自願公告 有關創勝集團合作夥伴Inhibrx公佈ozekibart治療軟骨肉瘤的 II期臨床試驗積極結果，計劃於2026年遞交BLA的業績進展 創勝集團醫藥有限公司 本公司董事會（「董事會」）欣然公佈，合作夥伴Inhibrx Biosciences, Inc. （「Inhibrx」，納斯達克代碼：INBX）公佈了註冊性臨床研究ChonDRAgon （n=206）的積極主要結果。該研究評估了ozekibart(INBRX-109)單藥相較安慰劑在 晚期或轉移性、 ...

Financial Data and Key Metrics Changes - In Q3 2025, revenue grew by 54% compared to Q3 2024, driven by key products [6][9] - Gross margin as a percentage of revenue was 83.6%, an increase of 1.4 percentage points year-over-year [9] - Earnings per share increased to $7.02, compared to $1.18 in Q3 2024 [10] Business Line Data and Key Metrics Changes - Revenue from key products accounted for $12 billion in the quarter, with significant contributions from immunology, oncology, and cardiometabolic health [11][12] - EBGLYSS prescriptions increased by 41% in Q3 2025 compared to Q2 2025 [11] - Mounjaro's total prescriptions grew by over 60% in the U.S. [14] Market Data and Key Metrics Changes - U.S. revenue increased by 45%, with strong volume growth from Zepbound and Mounjaro, despite a 15% decline in price [10] - International revenue increased by over 100% in constant currency, reflecting strong uptake of Mounjaro [10] - Japan, China, and the rest of the world saw constant currency revenue growth of 24%, 22%, and 51%, respectively [10] Company Strategy and Development Direction - The company is focused on expanding its manufacturing footprint and has announced plans for new facilities in the U.S. [7][8] - Lilly aims to leverage its robust pipeline and R&D investments to maintain a competitive edge in the market [51][53] - The company is pursuing an "all of the above" strategy to expedite the launch of orforglipron [39] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong performance and market share gains in the incretin analogs market [6][9] - The company raised its revenue and earnings per share guidance for the year based on strong financial performance [6][15] - Management acknowledged the competitive landscape but emphasized confidence in their portfolio and execution strategy [51][53] Other Important Information - The company distributed $1.3 billion in dividends and executed approximately $700 million in share repurchases during the quarter [8] - Lilly achieved several key milestones, including FDA approvals and positive trial results for multiple products [7][26] Q&A Session Summary Question: Comments on orforglipron and its market launch - Management indicated a focus on getting orforglipron to patients quickly and is pursuing various strategies to expedite its launch [39] Question: Insights on Mounjaro's international ramp - Management noted strong performance in new markets and emphasized the importance of patient activation for obesity treatment [46] Question: Market dynamics and competitor behavior - Management expressed confidence in their competitive position and highlighted ongoing investments in R&D and execution [51][53] Question: Pricing and volume dynamics for orforglipron - Management discussed the importance of understanding price elasticity and the potential for significant market expansion with orforglipron [85]

Summary of Tectonic Therapeutic (NasdaqGM:TECX) Conference Call on TX45 Phase 1B Part B Results Company Overview - **Company**: Tectonic Therapeutic - **Product**: TX45 - **Focus**: Treatment for pulmonary hypertension associated with reduced ejection fraction heart failure (PHFREF) Key Points from the Conference Call Clinical Trial Results - **Trial Design**: Phase 1B clinical trial evaluated safety and hemodynamic effects of TX45 in 14 patients with PHFREF [2][3] - **Primary Endpoint**: Mean change from baseline in pulmonary vascular resistance (PVR) for patients with PVR ≥ 3 WU [4] - **Results**: TX45 was well tolerated, showing improvements in all hemodynamic measurements evaluated [3][12] - **Wedge Pressure**: Decreased by over 6 mmHg, translating to a 29% reduction from baseline [13] - **PVR Reduction**: Approximately 20% reduction in PVR for patients with PVR ≥ 3 WU [14] - **Cardiac Output**: Increased by approximately 17% [16] - **Mean Pulmonary Artery Pressure**: Decreased by 19% [16] - **Ejection Fraction Improvement**: Left ventricular ejection fraction improved from 34% at baseline to 40.3% at day 29, representing a 19% increase [17] Market Potential - **Patient Population**: Approximately 1.1 million people in the U.S. with PHFREF, with around 300,000 having CPCPH and PVR ≥ 3 [6] - **Need for Treatment**: Significant need for new treatments due to worse exercise capacity and increased mortality in patients with pulmonary hypertension [5] Future Clinical Trials - **APEX Phase 2 Trial**: Ongoing trial with over 50% enrollment, focusing on patients with PVR ≥ 3 WU [21] - **Upcoming Studies**: Plans to initiate a study for TX45 in pulmonary hypertension associated with interstitial lung disease (PHILD) [22] - **Financial Health**: Company has a financial runway into Q4 2028 [22] Safety and Tolerability - **Adverse Events**: No serious or severe adverse events reported; only mild to moderate procedure-related back pain observed [12] - **Vital Signs**: No clinically significant changes in vital signs, ECG, or lab values [12] Discussion Points - **Correlation with Exercise Capacity**: Data suggests that improvements in hemodynamics may correlate with increased exercise tolerance, although exact predictions for 6-minute walk tests remain uncertain [20] - **Data Consistency**: Consistency of results across different patient populations was noted, reinforcing confidence in TX45's efficacy [23][26] Regulatory and Development Considerations - **Future Steps**: Potential for a Phase 2/3 trial for HFREF, depending on APEX trial results and regulatory alignment [57] Additional Insights - **Echocardiographic Data**: Persistent improvements in left ventricular function and pulmonary hemodynamics observed up to 29 days post-dose [17][19] - **Outlier Impact**: Discussion on the impact of an outlier patient on mean and median hemodynamic results, highlighting variability in small sample sizes [33][34] This summary encapsulates the critical findings and future directions for Tectonic Therapeutic's TX45, emphasizing its potential impact on treating PHFREF and the company's strategic plans moving forward.

Core Insights - Heng Rui Medicine announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of injection-use Ruikang Trastuzumab [1] Group 1: Clinical Trial Details - The clinical trial will focus on Ruikang Trastuzumab as a monotherapy compared to Docetaxel + Carboplatin + Trastuzumab + Pertuzumab for neoadjuvant treatment of early-stage or locally advanced HER2-positive breast cancer [1] - This study is a randomized, open-label, multi-center Phase III clinical trial [1] Group 2: Product Approval and Indications - Injection-use Ruikang Trastuzumab has already been approved for use in China, specifically for adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have HER2 activation mutations and have previously received at least one systemic treatment [1]